Published in AIDS Res Hum Retroviruses on October 01, 2007
Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr (2009) 3.41
Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis. AIDS (2014) 2.10
Treatment outcomes of HIV-infected adolescents attending public-sector HIV clinics across Gauteng and Mpumalanga, South Africa. AIDS Res Hum Retroviruses (2013) 1.67
Do HIV-infected women want to discuss reproductive plans with providers, and are those conversations occurring? AIDS Patient Care STDS (2010) 1.56
Survival of HIV-infected adolescents on antiretroviral therapy in Uganda: findings from a nationally representative cohort in Uganda. PLoS One (2011) 1.56
Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa. BMC Infect Dis (2012) 1.50
Improving health outcomes for youth living with the human immunodeficiency virus: a multisite randomized trial of a motivational intervention targeting multiple risk behaviors. Arch Pediatr Adolesc Med (2009) 1.46
Post-HAART outcomes in pediatric populations: comparison of resource-limited and developed countries. Pediatrics (2011) 1.41
Impact on ART initiation of point-of-care CD4 testing at HIV diagnosis among HIV-positive youth in Khayelitsha, South Africa. J Int AIDS Soc (2013) 1.28
Antiretroviral therapy outcomes among adolescents and youth in rural Zimbabwe. PLoS One (2012) 1.26
The impact of stigma on medication adherence among HIV-positive adolescent and young adult females and the moderating effects of coping and satisfaction with health care. AIDS Patient Care STDS (2011) 1.24
HIV-infected adolescents in southern Africa can achieve good treatment outcomes: results from a retrospective cohort study. AIDS (2013) 1.09
Predictors of suboptimal virologic response to highly active antiretroviral therapy among human immunodeficiency virus-infected adolescents: analyses of the reaching for excellence in adolescent care and health (REACH) project. Arch Pediatr Adolesc Med (2009) 1.03
Early patterns of adherence in adolescents initiating highly active antiretroviral therapy predict long-term adherence, virologic, and immunologic control. AIDS Patient Care STDS (2009) 0.96
Contraceptive methods and risk of HIV acquisition or female-to-male transmission. Curr HIV/AIDS Rep (2014) 0.88
Viral suppression in adolescents on antiretroviral treatment: review of the literature and critical appraisal of methodological challenges. Trop Med Int Health (2016) 0.83
Factors associated with self-reported adherence among adolescents on antiretroviral therapy in Zimbabwe. AIDS Care (2014) 0.82
Characteristics of HIV infected adolescents in Latin America: results from the NISDI pediatric study. J Trop Pediatr (2010) 0.82
Factors associated with lack of antiretroviral adherence among adolescents in a reference centre in Rio de Janeiro, Brazil. Int J STD AIDS (2008) 0.81
Risk of death among those awaiting treatment for HIV infection in Zimbabwe: adolescents are at particular risk. J Int AIDS Soc (2015) 0.80
Nine-year follow-up of HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy. Germs (2013) 0.80
Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation. Pediatrics (2014) 0.79
Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression. AIDS Res Hum Retroviruses (2009) 0.78
Comparing longitudinal CD4 responses to cART among non-perinatally HIV-infected youth versus adults: Results from the HIVRN Cohort. PLoS One (2017) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol (2003) 5.43
Reduced lopinavir exposure during pregnancy. AIDS (2006) 3.98
Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med (2010) 3.81
Identification of a candidate therapeutic autophagy-inducing peptide. Nature (2013) 3.76
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis (2007) 3.75
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One (2009) 3.40
Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med (2002) 3.31
Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med (2010) 3.14
Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus. Arch Pediatr Adolesc Med (2005) 2.60
Beyond drug use: a systematic consideration of other outcomes in evaluations of treatments for substance use disorders. Addiction (2011) 2.58
Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med (2012) 2.50
Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis (2011) 2.42
Adherence to antiretrovirals among US women during and after pregnancy. J Acquir Immune Defic Syndr (2008) 2.38
Human bocavirus: prevalence and clinical spectrum at a children's hospital. Clin Infect Dis (2006) 2.38
Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. AIDS (2008) 2.35
Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS (2009) 2.29
Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol (2002) 2.28
Depressive and anxiety disorders in women with HIV infection. Am J Psychiatry (2002) 2.26
The use of cell phone reminder calls for assisting HIV-infected adolescents and young adults to adhere to highly active antiretroviral therapy: a pilot study. AIDS Patient Care STDS (2006) 2.20
Factors associated with lack of viral suppression at delivery among highly active antiretroviral therapy-naive women with HIV: a cohort study. Ann Intern Med (2015) 2.13
Comparison of methods to account for implausible reporting of energy intake in epidemiologic studies. Am J Epidemiol (2015) 2.11
Cigarettes butts and the case for an environmental policy on hazardous cigarette waste. Int J Environ Res Public Health (2009) 2.05
Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet (2003) 2.04
Transgender female youth and sex work: HIV risk and a comparison of life factors related to engagement in sex work. AIDS Behav (2009) 2.04
Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J Infect Dis (2004) 1.98
Perinatal HIV counseling and rapid testing in Tijuana, Baja California, Mexico: seroprevalence and correlates of HIV infection. J Acquir Immune Defic Syndr (2006) 1.83
A prospective, randomized trial of clear liquids versus low-fat solid diet as the initial meal in mild acute pancreatitis. Clin Gastroenterol Hepatol (2007) 1.74
Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. Am J Psychiatry (2002) 1.73
In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS (2007) 1.70
Vitamin D inhibits human immunodeficiency virus type 1 and Mycobacterium tuberculosis infection in macrophages through the induction of autophagy. PLoS Pathog (2012) 1.69
Syndemic theory and HIV-related risk among young transgender women: the role of multiple, co-occurring health problems and social marginalization. Am J Public Health (2012) 1.68
Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr (2008) 1.65
Human immunodeficiency virus type-1 infection inhibits autophagy. AIDS (2008) 1.65
Management of the transgender adolescent. Arch Pediatr Adolesc Med (2011) 1.64
An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS (2013) 1.64
The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men. J Acquir Immune Defic Syndr (2013) 1.63
Health care transition for youth living with HIV/AIDS. Pediatrics (2011) 1.62
Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J Infect Dis (2009) 1.61
Delayed onset of pubertal development in children and adolescents with perinatally acquired HIV infection. J Acquir Immune Defic Syndr (2003) 1.60
Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes. J Acquir Immune Defic Syndr (2011) 1.55
Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS (2010) 1.54
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS (2007) 1.53
A holist's anxiety of influence: commentary on Kirshner. J Am Psychoanal Assoc (2012) 1.52
Psychiatric hospitalizations among children and youths with human immunodeficiency virus infection. Pediatrics (2004) 1.51
Barriers to medication adherence in behaviorally and perinatally infected youth living with HIV. AIDS Behav (2013) 1.51
Vitamin D status in adolescents and young adults with HIV infection. Am J Clin Nutr (2006) 1.49
Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. AIDS (2015) 1.49
Stigma and sexual health risk in HIV-positive African American young men who have sex with men. AIDS Patient Care STDS (2010) 1.48
Immune suppression and immune activation in depression. Brain Behav Immun (2010) 1.48
Hormonally active vitamin D3 (1alpha,25-dihydroxycholecalciferol) triggers autophagy in human macrophages that inhibits HIV-1 infection. J Biol Chem (2011) 1.48
Clinical outcomes after an unstructured treatment interruption in children and adolescents with perinatally acquired HIV infection. Pediatrics (2008) 1.47
Adolescents and HIV infection: the pediatrician's role in promoting routine testing. Pediatrics (2011) 1.47
Hepatitis C prevalence in children with perinatal human immunodeficiency virus infection enrolled in a long-term follow-up protocol. Arch Pediatr Adolesc Med (2004) 1.44
It is time to plan the tobacco endgame. BMJ (2014) 1.43
End-of-life care conversations with heart failure patients: a systematic literature review and narrative synthesis. Br J Gen Pract (2011) 1.42
Quality of life for children and adolescents: impact of HIV infection and antiretroviral treatment. Pediatrics (2006) 1.42
Psychoanalysis: practice and technique. J Am Psychoanal Assoc (2002) 1.39
Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age. AIDS (2012) 1.39
The discrete and the continuous in Freud's "remembering, repeating and working through". J Am Psychoanal Assoc (2014) 1.39
Is there a Usable Heidegger for Psychoanalysts? J Am Psychoanal Assoc (2016) 1.37
Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis (2004) 1.37
Co-occuring psychiatric symptoms in children perinatally infected with HIV and peer comparison sample. J Dev Behav Pediatr (2010) 1.36
HIV prevalence during pregnancy in Tijuana, Baja California, Mexico. AIDS (2003) 1.36
Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045. AIDS (2010) 1.35
Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. AIDS (2012) 1.35
Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother (2004) 1.35
Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J (2005) 1.35
Mental health treatment patterns in perinatally HIV-infected youth and controls. Pediatrics (2009) 1.34
Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr (2010) 1.33
Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. J Acquir Immune Defic Syndr (2007) 1.32
Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother (2006) 1.32
Sexual transmission risk behavior of adolescents With HIV acquired perinatally or through risky behaviors. J Acquir Immune Defic Syndr (2010) 1.32
Hepatitis C virus inhibits intracellular interferon alpha expression in human hepatic cell lines. Hepatology (2005) 1.31
The search for data on when to start treatment for HIV infection. J Infect Dis (2008) 1.31
Sexual risk taking among transgender male-to-female youths with different partner types. Am J Public Health (2009) 1.31
Predictors of antiretroviral medication adherence among a diverse cohort of adolescents with HIV. J Adolesc Health (2012) 1.29
Real-time RT-PCR for quantitation of hepatitis C virus RNA. J Virol Methods (2002) 1.29
Adolescent immunizations: a position paper of the Society for Adolescent Medicine. J Adolesc Health (2006) 1.28